Investor Relations

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained-delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9%, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

Jan 10, 2022
EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements
Jan 10, 2022
EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer
Dec 07, 2021
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU®
Nov 19, 2021
EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering
Nov 16, 2021
EyePoint Pharmaceuticals Announces Pricing of Public Offering

Stern Investor Relations
p. 212.362.1200

Amy Phillips
p. 412.327.9499